872511-35-8

Basic information

• Product Name: N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6- MethylpyriMidine-4,6-diaMine
• Synonyms: N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6- MethylpyriMidine-4,6-diaMine
• CAS NO: 872511-35-8
• Molecular Formula: C₁₇H₂₄N₆
• Molecular Weight: 312.41266
• Mol File: 872511-35-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6- MethylpyriMidine-4,6-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6- MethylpyriMidine-4,6-diaMine(872511-35-8)
• EPA Substance Registry System: N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6- MethylpyriMidine-4,6-diaMine(872511-35-8)

Safety Data

• Hazardous Substances Data: 872511-35-8(Hazardous Substances Data)

Usage

General Description

N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6-MethylpyriMidine-4,6-diaMine is a chemical compound that belongs to the class of pyrimidines. It contains a pyrimidine core with a substituted piperazine and an ethyl group. N4-(4-(4-ethylpiperazin-1-yl)phenyl)-N6- MethylpyriMidine-4,6-diaMine has potential pharmacological uses, as it may interact with receptors or enzymes in the body. It is important to handle this chemical with care and to follow proper safety protocols when working with it in a laboratory setting.

Upstream product

• 5308-25-8 4-ethylpiperazine 
• 115619-00-6 1-ethyl-4-(4-nitro-phenyl)-piperazine 
• 586-78-7 para-nitrophenyl bromide 
• 933702-18-2 (6-chloropyrimidin-4-yl)methylamine 
• 115619-01-7 4-(4-ethylpiperazin-1-yl)aniline 
• 65766-32-7 6-chloro-N-methylpyrimidin-4-amine 

Downstream Products

• 872511-34-7 NVP-BGJ398 
• 943189-14-8 3-(5-methoxy-3-trifluoromethyl-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea 

Relevant articles and documents

CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS

The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cance

CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF.

The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its mono

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.